Bioetica's Hemostanene
This article was originally published in The Gray Sheet
Executive Summary
Company's premarket approval application for the absorbable collagen hemostatic sponge is "approvable," the company announces Aug. 12. FDA has asked Portland, Maine-based Bioetica, Inc. to "submit additional information" within the next few weeks. The company notes that the sponge has "been evaluated in a multi- center clinical trial for use in a variety of surgical procedures as an adjunct for hemostasis when control by ligature or conventional procedures is ineffective or impractical." The sponge is manufactured by Bioetica's Lyon, France-based parent company, Coletica, SA
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.